Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Neumora Therapeutics, Inc. today and set a price target of $18.00.

Douglas Tsao has given his Buy rating due to a combination of factors tied to both clinical data and market opportunity. He views NMRA-511’s Phase 1b results in Alzheimer’s disease agitation as meaningfully positive, especially in patients with high anxiety, where the drug showed a stronger effect on aggressive behaviors than in the overall study population. The data suggest that NMRA-511’s anxiolytic mechanism could be particularly well suited to this subgroup, positioning it to become a key therapy for agitation in Alzheimer’s and potentially other anxiety-related conditions. In addition, the drug’s safety profile appears favorable, with a low discontinuation rate and a cleaner risk profile relative to the currently approved option, Rexulti, which carries a black box warning for increased mortality in elderly patients.

Tsao also highlights the substantial unmet need and commercial potential in this indication, given the large U.S. Alzheimer’s population and the high proportion of patients with significant anxiety who currently rely on therapies with limited effectiveness. He notes that the observed effect size in high-anxiety patients compares favorably with benchmark drugs like Rexulti and Auvelity, supporting the view that NMRA-511 could offer superior clinical benefit. The planned development path, including a multiple-ascending-dose extension and a Phase 2/3 dose-ranging trial, provides a clear catalyst roadmap into 2026. Combined with Neumora’s broader pipeline progress and multiple upcoming milestones, Tsao believes these factors justify a positive risk-reward profile and support his Buy rating and $18 price target.

In another report released today, Needham also maintained a Buy rating on the stock with a $8.00 price target.